To the full analysis
Thermo Fisher Scientific stock: growth
TMOThermo Fisher Scientific reported $44.56B in revenue for fiscal 2025, up 3.9% on the prior year, up 6.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13.8%
per year from 2006 to 2025, per share 10%
Earnings (Annual rate)
21.4%
per year from 2006 to 2025, per share 17.3%
Free cash flow (Annual rate)
16.8%
per year from 2006 to 2025, per share 12.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.7% | 10.1% | 13.8% |
| Revenue per share | 7.8% | 10.8% | 10.0% |
| Earnings | 1.1% | 13.1% | 21.4% |
| Earnings per share | 2.0% | 13.6% | 17.3% |
| Free cash flow | −1.6% | 10.1% | 16.8% |
| Free cash flow per share | −0.6% | 10.8% | 12.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $3.79B | $168.94M | $328.86M |
| 2007 | $9.75B | $761.1M | $1.31B |
| 2008 | $10.5B | $994.2M | $1.16B |
| 2009 | $10.11B | $850.3M | $1.45B |
| 2010 | $10.79B | $1.04B | $1.23B |
| 2011 | $11.73B | $1.33B | $1.42B |
| 2012 | $12.51B | $1.18B | $1.72B |
| 2013 | $13.09B | $1.27B | $1.73B |
| 2014 | $16.89B | $1.89B | $2.19B |
| 2015 | $16.97B | $1.98B | $2.39B |
| 2016 | $18.27B | $2.02B | $2.71B |
| 2017 | $20.92B | $2.23B | $3.5B |
| 2018 | $24.36B | $2.94B | $3.79B |
| 2019 | $25.54B | $3.7B | $4.05B |
| 2020 | $32.22B | $6.38B | $6.82B |
| 2021 | $39.21B | $7.73B | $7.02B |
| 2022 | $44.92B | $6.95B | $6.91B |
| 2023 | $42.86B | $6B | $6.93B |
| 2024 | $42.88B | $6.34B | $7.27B |
| 2025 | $44.56B | $6.74B | $6.29B |
Revenue by segment
How Thermo Fisher Scientific Inc. makes its money and how that has shifted. Names are as the company reports them.
- Consumables42%
- Service42%
- Instruments16%
Figures as a table
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Consumables | $12.58B | $13.11B | $18.53B | $22.61B | $20.62B | $17.6B | $17.59B | $18.66B | 41.9% |
| Service | $5.49B | $6.05B | $6.91B | $8.85B | $16.37B | $17.61B | $17.85B | $18.59B | 41.7% |
| Instruments | $6.29B | $6.39B | $6.78B | $7.75B | $7.92B | $7.65B | $7.45B | $7.3B | 16.4% |
| Total revenue | $24.36B | $25.54B | $32.22B | $39.21B | $44.92B | $42.86B | $42.88B | $44.56B | 100% |
Revenue by region
Where Thermo Fisher Scientific Inc. generates its revenue.
- United States52%
- Europe27%
- Asia Pacific18%
- Other4%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| United States | $22.5B | $23.03B | 51.7% |
| Europe | $10.86B | $11.83B | 26.5% |
| Asia Pacific | $7.96B | $8.1B | 18.2% |
| Other | $1.56B | $1.6B | 3.6% |
| Total revenue | $42.88B | $44.56B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Jan 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.